GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » EV-to-EBIT

Samsung BioLogics Co (XKRX:207940) EV-to-EBIT : 45.55 (As of May. 03, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Samsung BioLogics Co's Enterprise Value is ₩54,728,211 Mil. Samsung BioLogics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩1,201,583 Mil. Therefore, Samsung BioLogics Co's EV-to-EBIT for today is 45.55.

The historical rank and industry rank for Samsung BioLogics Co's EV-to-EBIT or its related term are showing as below:

XKRX:207940' s EV-to-EBIT Range Over the Past 10 Years
Min: -364.24   Med: 59.37   Max: 203.24
Current: 45.54

During the past 10 years, the highest EV-to-EBIT of Samsung BioLogics Co was 203.24. The lowest was -364.24. And the median was 59.37.

XKRX:207940's EV-to-EBIT is ranked worse than
84.7% of 438 companies
in the Biotechnology industry
Industry Median: 8.795 vs XKRX:207940: 45.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Samsung BioLogics Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩53,945,297 Mil. Samsung BioLogics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩1,201,583 Mil. Samsung BioLogics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.23%.


Samsung BioLogics Co EV-to-EBIT Historical Data

The historical data trend for Samsung BioLogics Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co EV-to-EBIT Chart

Samsung BioLogics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 158.04 193.51 103.59 53.82 44.90

Samsung BioLogics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.82 50.98 47.27 39.12 44.90

Competitive Comparison of Samsung BioLogics Co's EV-to-EBIT

For the Biotechnology subindustry, Samsung BioLogics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Samsung BioLogics Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Samsung BioLogics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Samsung BioLogics Co's EV-to-EBIT falls into.



Samsung BioLogics Co EV-to-EBIT Calculation

Samsung BioLogics Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=54728210.888/1201583.334
=45.55

Samsung BioLogics Co's current Enterprise Value is ₩54,728,211 Mil.
Samsung BioLogics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,201,583 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Samsung BioLogics Co  (XKRX:207940) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Samsung BioLogics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1201583.334/53945296.888
=2.23 %

Samsung BioLogics Co's Enterprise Value for the quarter that ended in Dec. 2023 was ₩53,945,297 Mil.
Samsung BioLogics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,201,583 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Samsung BioLogics Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Samsung BioLogics Co (XKRX:207940) Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu,, Incheon, KOR
Samsung BioLogics Co Ltd engaged in development and manufacturing of bio-healthcare products.The Company works namely in Process Development, cGMP Manufacturing, Aseptic Fill and Finish.

Samsung BioLogics Co (XKRX:207940) Headlines

No Headlines